钼靶X射线摄片与血清CEA、CA19-9、CA15-3联合检查对乳腺癌的临床诊断价值

Clinical Diagnostic Value of Molybdenum Target X-ray Combined with Serum CEA,CA19-9 and CA15-3 in the Detection of Breast Cancer

为探讨乳腺钼靶X射线摄片与血清CEA、CA19-9、CA15-3联合检查对乳腺癌的临床诊断价值,对87例经手术及病理证实的乳腺疾病患者的CEA、CA19-9、CA15-3检测结果和乳腺钼靶X射线征象作回顾性统计分析。结果显示:乳腺癌组的三项血清学指标远远大于良性病变组和正常对照组(P<0.01),与良性病变组比较,t值分别为3.2903、3.8996、4.5236,P均<0.01;与正常对照组比较,t值分别为4.3428、5.0101、5.9098,P均<0.01。乳腺良性病变组与正常对照组比较,t值分别为1.6378、0.6346、1.2225,P均>0.05。CEA、CA19-9、CA15-3、钼靶X射线摄片四项联合检查的敏感性较单独检测有明显提高(P<0.01),乳腺癌组单项检查与四项联合检查比较,χ2值分别为55.008、47.868、24.901、13.818,P<0.01。结论:对乳腺癌患者CEA、CA19-9、CA15-3进行联合检测和钼靶X射线摄片检查可以提高其检出率,对于早期诊断、治疗和监视、随访有临床意义。

To explore the clinical diagnostic value of CR molybdenum target x-ray combined with CEA, CA199 and CA153 in the detection of breast cancer, there were 87 cases of breast disease confirmed by surgery and pathology. The results of CEA, CA199, CA153 and the signs of CR Molybdenum target x-ray were statistical analyzed retrospectively. The results showed that the serum levels of CEA, CA199 and CA153 in breast cancer group were higher than that in benign lesions group and normal control group （ P 〈 0.01 ）. The sensitivity of CEA, CA199, CA153 combined with CR molybdenum target x-ray was better than any one of them （P 〈 0.01 ）. The combined detection of CEA, CA199, CA153 and CR Molybdenum target x-ray in breast cancer patients can improve the detective rate; it plays an important role in early diagnosis, treatment and monitoring.